Ultra V took part in the Kimes 2024... ‘UltraCol’ global competitivene…
페이지 정보
작성자 ultrav 작성일24-08-06 15:22 조회114회관련링크
본문
Ultra V took part in the Kimes 2024... ‘UltraCol’ global competitiveness reaffirmed at an all-time high
Bio Medical Beauty Group Ultra V (CEO Hanjin Kwon) participates in the 39th Korean International Medical & Hospital Equipment Show KIMES held at COEX in Samseong-dong, Gangnam-gu, Seoul from March 14 to 17. It was announced that the four-day schedule was successfully completed.
KIMES, a representative festival of the health industry, is early in the spotlight as a venue for introducing technology and information exchange and global market trends in the medical device-related industry. This year, with the theme of ‘Better Life, Better Future’, over 1,350 domestic and foreign manufacturers participated and introduced over 35,000 items including convergence medical devices, hospital equipment, medical information systems, healthcare/rehabilitation devices, and medical-related supplies.
At the KIMES 2024 exhibition, Ultra V introduced all his products, including PDO and PCL absorbable threads with its own technology, which were major export items, as well as the Idebenone cosmetic line and Tridem device, which received European CE certification. From the first day, visitors to the KIMES 2024 exhibition, buyers and companies from around the world visited the Ultra V booth, creating a crowd, and the excitement continued for four days.
The main product introduced at this exhibition is the world’s first PDO microsphere ‘UltraCol’, ‘UltraCol’ is a product developed with Ultra V’s proprietary technology and consists of microspheres made of PDO (Polydioxanone), a component that is harmless to the human body.
A company official said, "The time it stays in the body is shorter than that of other collagen regeneration-inducing injection procedures, and 'UltraCol' injected into the skin is absorbed into the body while inducing autologous collagen production, so there is a low possibility of developing nodules and granulomas. “If the particles are sharp, the contact area increases and the possibility of foreign body reaction is high, but Ultracol has the characteristic of being spherical, so there is less foreign body sensation and the injection can be performed even on thin skin.”
Recognized for its excellence in the world's first PDO material filler manufacturing and mass production technology, it won the IR52 Jang Young-sil Award in 2020. It has a history of winning the Korea Patent Award, has KFDA certification from the Korean Ministry of Food and Drug Safety and CE certification from Europe, and has already been sold in Asia, Europe, South America, and Korea.
Meanwhile, Ultra V recently announced that it is currently conducting a biological safety evaluation for ‘UltraCol’ to be launched in mainland China after completing approval in Hainan Province, China, and plans to submit for clinical trials within 3 months.
